Abstract: Mouse milk fat globule epidermal growth factor 8 (MFG-E8), which is secreted by a subset of activated macrophages, binds to apoptotic cells by recognizing phosphatidylserine and promotes their engulfment. Many apoptotic cells are left unengulfed in the germinal centers of the spleen in MFG-E8 ؊/؊ mice, and these mice develop an autoimmune disease resembling human systemic lupus erythematosus (hSLE). Here, we report that hMFG-E8 bound to phosphatidylserine and an integrin ␣ v ␤ 3 complex. Increasing concentrations of MFG-E8 generated a bell-shaped response curve for the efficiency of phagocytosis. That is, in NIH3T3 and MFG-E8 ؊/؊ thioglycollate-elicited peritoneal macrophages that do not express MFG-E8, hMFG-E8 enhanced engulfment at low concentrations but inhibited it at high concentrations. On the other hand, hMFG-E8 dose-dependently inhibited the engulfment of apoptotic cells by MFG-E8 ؉/؉ thioglycollate-elicited peritoneal macrophages, indicating that an excess of MFG-E8 has an inverse effect on the engulfment of apoptotic cells. To investigate the role of MFG-E8 in human disease, we generated two mAb against MFG-E8 and screened human blood samples for MFG-E8 using an ELISA. We found that some childhood-onset and adult SLE patients carried a significant level of MFG-E8 in their blood samples. These results suggested that the aberrant expression of MFG-E8 is involved in the pathoetiology of some cases of hSLE. J. Leukoc. Biol. 83: 000 -000; 2008.
INTRODUCTION
Many cells undergo programmed cell death during development, lymphocyte maturation, and normal cell turnover [1, 2] .
Programmed cell death can be divided into two steps: apoptosis and the clearance of dead cells [3] . In apoptosis, proteases of the caspase family are activated and cleave more than 300 cellular proteins that are essential for cell survival [4, 5] . A specific nuclease [caspase-activated DNase (CAD)] is activated by caspase and cleaves the chromosomal DNA into nucleosomal units. Morphological changes of the cells and DNA fragmentation induced by caspase and CAD are hallmarks of apoptotic cell death. The dead apoptotic cells are then swiftly recognized by phagocytes, and their cellular components are degraded into nucleotides and amino acids in the phagocyte lysosomes [6 -8] .
If the engulfment is inefficient, the apoptotic cells undergo secondary necrosis and release noxious and antigenic materials into the circulation, which may cause severe tissue damage and/or drive an autoimmune response. For example, a large number of short-lived neutrophils are activated during inflammation. If the dead neutrophils are not efficiently cleared, noxious and toxic materials released from the dead neutrophils may damage the tissues [9, 10] . Systemic lupus erythematosus (SLE) is a multifactorial disease characterized by the presence of high titers of autoantigens against nuclear components (antinuclear and anti-DNA antibodies) [11] . A high concentration of the histone-DNA complex or nucleosomes can be found in the serum of SLE patients [12, 13] . Herrmann's groups [14, 15] proposed that these autoantigens are released by dead apoptotic cells that escaped engulfment.
Many ligand and receptors have been proposed to function in the engulfment of apoptotic cells. These include scavenger receptors (CD36, CD68, and lipoxygenase 1), calreticulin, CD14, ABC1 transporter, Mer kinase receptor, and vitronectin receptor (␣ v ␤ 3 integrin) [6] . In addition, one of the earliest changes in apoptotic cells is the caspase-dependent exposure of phosphatidylserine, and liposomes carrying phosphatidylserine specifically inhibit the engulfment of apoptotic cells by macrophages, suggesting the presence of receptors or adaptors that specifically recognize phosphatidylserine [16] .
We previously identified mouse milk fat globule epidermal growth factor (EGF) 8 (mMFG-E8; also called lactadherin or BA46 in human) as a glycoprotein that binds phosphatidylserine on apoptotic cells and stimulates the engulfment of apoptotic cells by macrophages [17] . MFG-E8 is expressed in thioglycollate-elicited peritoneal macrophages, tingible-body macrophages in the spleen and lymph nodes, and Langerhans cells in the skin [17] [18] [19] . Mice deficient in MFG-E8, particularly female mice, show defective engulfment of apoptotic cells in the germinal centers of the spleen [18] . They carry a high level of antinuclear and anti-DNA antibodies in their serum, and they suffer from glomerular nephritis, which resembles that found in human (h)SLE patients.
In this report, we characterized the role of hMFG-E8 in the engulfment of apoptotic cells and explored its possible role in human disease. hMFG-E8 bound to phosphatidylserine and a soluble recombinanat (r)␣ v ␤ 3 integrin complex with high affinity. At low concentration, MFG-E8 stimulated the engulfment of apoptotic cells, but it inhibited their engulfment at high concentration. In particular, an excess of hMFG-E8 dosedependently inhibited the engulfment of apoptotic cells in thioglycollate-elicited peritoneal macrophages that normally use MFG-E8 for engulfment of apoptotic cells. Using two mAb against hMFG-E8, we established a sensitive ELISA system and used it to screen human blood samples. We found that some hSLE patients had a high serum level of MFG-E8.
MATERIALS AND METHODS
Mice, Armenian hamsters, and cell lines CAD Ϫ/Ϫ and MFG-E8 Ϫ/Ϫ mice were described previously [18, 20] . C57BL/6 mice and Armenian hamsters were purchased from SLC (Shizuoka, Japan) and Oriental Yeast (Tokyo, Japan), respectively. Mouse NIH3T3 cells expressing ␣ v ␤ 3 integrins were described previously [17] and were grown in DMEM containing 10% FCS (Gibco, Gaithersburg, MD, USA). To prepare thioglycollate-elicited peritoneal macrophages, 8-week-old C57BL/6 mice were treated i.p. with 2 ml thioglycollate (Sigma Chemical Co., St. Louis, MO, USA). Four days later, peritoneal macrophages were prepared and cultured in DMEM containing 10% FCS. Human U937 cells (ATCC CRL-1593.2) and monkey COS-7 cells (ATCC CRL-1651) were maintained in DMEM supplemented with 10% FCS. A derivative of Chinese hamster ovary (CHO) cells with multiple glycosylation defects (CHO lec 3.2.8.1) was described previously [21] . All animal experiments were carried out in accordance with protocols approved by the Osaka University Animal Care and Use Committee (Japan) as well as by the Kyoto University Animal Care and Use Committee (Japan).
Cloning of hMFG-E8 cDNA
Total RNA was extracted from human U937 cells using the RNeasy kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. RNA was reverse-transcribed with RNase H -RT (Invitrogen, Carlsbad, CA, USA) and subjected to PCR with primers specific to hMFG-E8 (5Ј-CGCCCGCGTC-CCCGCAGCAT-3Ј and 5Ј-TCTAGCTAGCACAGCCCAGCAGCTC-3Ј). Amplified cDNA was cloned into the pGEM-T-EASY vector (Promega, Madison, WI, USA) and verified by DNA sequencing.
Recombinant proteins and peptide
To produce hMFG-E8, a DNA fragment encoding the FLAG epitope was ligated to the C-terminal end of hMFG-E8 cDNA. The resulting construct was inserted into the mammalian expression vector pEF-BOS [22] and introduced into COS-7 cells by electroporation [23] . In brief, 5 ϫ 10 6 cells were transfected with 20 g DNA and cultured in DMEM supplemented with 1% FCS. The medium was changed 12 h after transfection, and the cells were cultured further. Forty-eight hours later, the culture supernatant was collected, and hMFG-E8 was purified using anti-Flag M2 affinity gel (Sigma Chemical Co.).
The His-tagged soluble, clasped human integrin ␣ v (␣ v -AHCys) and ␤ 3 (␤ 3 -tev-BHCys), was produced in CHO lec 3.2.8.1 cells as described previously [24] , collected from the culture supernatant using Ni-NTA agarose (Qiagen), and purified by gel filtration (Superdex 200HR). Sepharose 4B was conjugated with the 2H11 mAb (a gift from Dr. Ellis Reinherz, Dana-Farber Cancer Institute, Boston, MA, USA), which recognizes the Acid-Base heterodimeric region [25] , and used to purify the clasped ␣ v ␤ 3 complex. In brief, samples from the gel-filtration step were loaded onto 2H11 mAb-conjugated Sepharose 4B, and the resin was washed with 10 mM Tris-HCl (pH 8.0) containing 150 mM NaCl, 1 mM CaCl 2 , and 1 mM MgCl 2 . The bound protein was then eluted with 50 mM triethylamine (pH 11.5) containing 150 mM NaCl, 1 mM CaCl 2, and 1 mM MgCl 2 and dialyzed against PBS containing 1 mM CaCl 2 and 1 mM MgCl 2 .
A peptide [Gly-Arg-Gly-Asp-Asn-Pro (GRGDNP)] carrying an Arg-Gly-Asp (RGD) motif was purchased from Gibco.
Protein lipid overlay assay and solid-phase ELISA
The binding of hMFG-E8 to phospholipid was analyzed by the protein lipid overlay assay using PIP Strips (Molecular Probes, Eugene, OR, USA). Briefly, after the nonspecific-binding sites were blocked by treatment with 3% (w/v) BSA in TBST (Tris-buffered saline containing 0.1% Tween 20), and the membrane was incubated at room temperature for 1 h with 0.5 g/ml hMFG-E8, washed with TBST, and incubated with HRP-conjugated anti-Flag antibody (Sigma Chemical Co.). The bound protein was detected using the Western Lightening chemiluminescence reagent (PerkinElmer, Wellsley, MA, USA).
The solid-phase ELISA for hMFG-E8 binding to phosphatidylserine was carried out as described [26] . In brief, L-␣-phosphatidyl-L-serine (3 g/ml, 100 l, Avanti Polar Lipids, Alabaster, AL, USA) in methanol was added to a 96-well microtiter plate and air-dried. After treatment with 1% (w/v) BSA in PBS, hMFG-E8 diluted to the appropriate concentration was added to the wells, and the plates were incubated at room temperature for 30 min. After a wash with PBS containing 0.05% Tween 20, the hMFG-E8 bound to the wells was quantified by ELISA with a biotinylated anti-Flag antibody (Sigma Chemical Co.) and HRP-conjugated streptavidin (Roche, Basel, Switzerland). The peroxidase activity was detected using a peroxidase-detecting kit (Sumitomo Bakelite, Tokyo, Japan) with o-phenylenediamine as the substrate. The absorbance was measured at 492 nm (A 492 ).
Binding of the ␣ v ␤ 3 integrin to MFG-E8 was examined by solid-phase ELISA. In brief, 96-well Maxisorp plates (Nalge Nunc International, Rochester, NY, USA) were coated with hMFG-E8 by incubating them overnight at 4°C with 50 l/well 10 g/ml hMFG-E8 in 50 mM sodium bicarbonate buffer (pH 9.6). After blocking nonspecific binding sites with TBS containing 10 mg/ml BSA, biotinylated ␣ v ␤ 3 integrin in TBS containing 1 mM MnCl 2 was added to the wells, and the plates were incubated at room temperature for 5 h. The bound ␣ v ␤ 3 integrin was detected with HRPconjugated streptavidin and 2,2Ј-azino-bis-(3-ethylbenzthiazoline-6-sulfonic acid)-diammonium salt (Zymed Laboratories, South San Francisco, CA, USA) as the substrate. A 405 was measured.
Phagocytosis assay
Phagocytosis was assayed with NIH3T3 cell transformants expressing ␣ v ␤ 3 integrin or thioglycollate-elicited peritoneal macrophages as described previously [17] . In brief, NIH3T3 cells or macrophages were cultured in 8-well Lab-Tek II chamber slides (Nalge Nunc International). Thymocytes from 9-week-old CAD-null mice [20] were incubated for 4 h at 37°C with 10 M dexamethasone. Apoptotic thymocytes were added to the phagocytes and incubated at 37°C. After fixation with 1% paraformaldehyde, the adherent cells were subjected to the TUNEL assay using an ApopTag peroxidase in situ apoptosis detection kit (Chemicon, Temecula, CA, USA), and the number of TUNEL-positive cells was counted. The phagocytosis index was determined as the number of TUNEL-positive cells per phagocytes. At least 150 phagocytes were tested.
Antibodies
Armenian hamsters and C57BL/6 mice were given two s.c. injections of 100 g hMFG-E8 with a 4-week interval. For the first injection, the hMFG-E8 was mixed with CFA; the second was mixed with IFA. A final injection of 20 g hMFG-E8 protein was given into the foot pads. Three days later, popliteal and inguinal lymph nodes were collected, and the lymphocytes were fused with mouse myeloma NSO overexpressing Bcl-2 [27] with a ratio of 5:1. Hybridomas were selected in hypoxanthine aminopterin thymidine medium (Behringer Ingelheim, Ingelheim, Germany), and supernatants from growth-positive wells were tested by ELISA for their ability to recognize hMFG-E8. Among several positive hybridomas, two (mouse mAb 1-H3 and hamster mAb 2-8E4A) were cloned by limiting dilution and grown in GIT medium (Nihon Pharmaceutical Co. Tokyo, Japan). The mAb were purified by Protein A-or Protein GSepharose (Pharmacia, Uppsala, Sweden). Biotinylation of the antibody was carried out with sulfosuccinimidyl 6-biotin-amido hexanoate (Pierce, Rockford, IL, USA), according to the manufacturer's instructions.
Sera of human patients and ELISA for hMFG-E8
After obtaining informed consent, we collected serum samples from patients at Osaka University Hospital and Yokohama City University Hospital (Japan) and plasma samples from patients at Nara Medical University (Japan). Our study protocol was approved by the ethics committee of the Graduate School of Medicine, Osaka University, and the Graduate School of Medicine, Kyoto University.
An indirect sandwich ELISA was developed to measure hMFG-E8 in the serum or plasma. A 96-well Maxisorp plate was coated with 1 g/well of the mouse anti-hMFG-E8 mAb (clone 1-H3) in 50 mM sodium bicarbonate buffer (pH 9.6) and incubated with Reagent Diluent Concentrate 2 (R&D Systems, Minneapolis, MN, USA). To human serum or plasma samples, Triton X-100 was added at the final concentration of 1%, diluted 10 times with TBS, and a 50 l-aliquot was added to the well. After incubation at room temperature for 1 h, the wells were washed with wash buffer of the Ampli Q kit (Dako, Denmark). The wells were then incubated at room temperature for 1 h with 0.8 g/ml biotinylated hamster mAb (clone 2-8E4A), washed as above, and incubated with 8000ϫ diluted alkaline phosphatase (AP)-conjugated streptavidin (Dako) for 30 min. AP activity was determined using the Ampli Q kit. Recombinant (r)hMFG-E8 diluted with 10% healthy donor serum or plasma was used to prepare the standard curve.
RESULTS

hMFG-E8
In mouse and rat systems, there are two splice variants for MFG-E8 mRNA: the long and short forms [17, 28] . The long form of rat MFG-E8 and mMFG-E8 has an extra exon that encodes a proline/threonine-rich (P/T) domain, and it has a higher affinity for phosphatidylserine than the short form. No splice variant has been reported for hMFG-E8 [29] . We screened the human U937 macrophage cell line for MFG-E8 mRNA by RT-PCR and obtained a single species of hMFG-E8 with a sequence identical to that reported by Couto et al. [29] . hMFG-E8 is synthesized as a protein of 387 amino acids. It is composed of a signal sequence (22 amino acids), one EGF-like domain carrying an RGD motif (46 amino acids), and two factor 8 C1/C2-like domains (316 amino acids; Fig. 1A) . On the chromosomal DNA of hMFG-E8 (National Center for Biotechnology Information GenBank Accession Number WC_000015), no exon-like sequences for extra domains were found in the corresponding region, indicating that there is no splice variant for hMFG-E8 that encodes the first EGF (E1) and the P/T domain.
To characterize hMFG-E8, its recombinant protein (tagged with Flag) was produced in COS-7 cells and purified to homogeneity. As shown in Figure 1B , the purified hMFG-E8 showed a single band of 46 kDa on SDS-PAGE. The difference from the estimated molecular weight (40,861) for the mature hMFG-E8 (365 amino acids) may be explained by glycosylation on three potential N-glycosylation sites (NXS or NXT). hMFG-E8 is significantly smaller than mMFG-E8-L (441 amino acids), which migrates to 72 kDa. The higher-thanpredicted molecular weight for mMFG-E8-L is probably owing to the additional EGF and P/T domains and to the presence of two additional N-glycosylation sites.
Binding of hMFG-E8 to phosphatidylserine and integrin ␣ v ␤ 3
We next determined the binding parameters of hMFG-E8 to phosphatidylserine. mMFG-E8 specifically binds phosphatidylserine through its factor 8-homologous domain, but it shares only 65% identity with the corresponding amino acid sequence of hMFG-E8. Furthermore, hMFG-E8 does not benefit from the enhanced binding conferred on mMFG-E8-L by the P/T-rich domain [17] . Therefore, it seemed likely that hMFG-E8 might have a significantly lower binding affinity for phosphatidylserine than mMFG-E8-L.
hMFG-E8 binding was determined by coating microtiter plates with phosphatidylserine and incubating them with increasing concentrations of hMFG-E8. We found that hMFG-E8 bound phosphatidylserine with a dissociation constant (K d ) of 20 nM, which was approximately 10 times higher than that of mMFG-E8 (Fig. 2A) . The specificity for phosphatidylserine was well-conserved, and hMFG-E8 did not bind the other phospholipids tested, including phosphatidylcholine, phosphatidylethanolamine, and phosphatidylinositol. When cells undergo apoptosis, they expose phosphatidylserine on their surface [30] . Accordingly, hMFG-E8, like mMFG-E8 [17] , specifically bound to apoptotic cells but not healthy cells (data not shown).
Bovine MFG-E8 and mMFG-E8 have been reported to bind integrin ␣ v ␤ 3 [17, 26, 31] . However, this binding was shown only in cells that expressed MFG-E8 or ␣ v ␤ 3 -integrin, and indirect binding remained a possibility. To examine whether MFG-E8 binds integrin directly, we prepared a recombinant integrin ␣ v ␤ 3 ectodomain complex, in which the ␣ v and ␤ 3 subunits were artificially "clasped" (Fig. 2B) . We used this complex to assay integrin binding to hMFG-E8 on microtiter plates. As shown in Figure 2B , the ␣ v ␤ 3 integrin bound dosedependently to plates coated with hMFG-E8 but not with BSA with an apparent K d of 0.3 nM. This binding was inhibited by 10 M of an RGD motif-containing peptide (GRGDNP), indicating that the association of ␣ v ␤ 3 integrin with hMFG-E8 is via the RGD motif in its EGF domain.
Efficiency of engulfment of apoptotic cells shows a bell-shaped response to hMFG-E8
As shown above, hMFG-E8 binds directly to phosphatidylserine and to the ␣ v ␤ 3 integrin complex, suggesting that hMFG-E8 might function as a bridging molecule between apoptotic cells and phagocytes. To confirm this, the effect of hMFG-E8 on the engulfment of apoptotic cells was examined with NIH3T3 cells expressing the ␣ v ␤ 3 integrin. As shown in Figure 3A , increasing concentrations of hMFG-E8 enhanced the engulfment of apoptotic cells dose-dependently up to 0.8 g/ml. However, higher concentration of hMFG-E8 did not support engulfment, and almost no apoptotic cells were engulfed in the presence of 1.6 g/ml.
Thioglycollate-elicited peritoneal macrophages abundantly express MFG-E8 and efficiently engulf apoptotic cells in a MFG-E8-dependent manner [17, 18, 32] . When the engulfment of apoptotic thymocytes with these macrophages was carried out in the presence of hMFG-E8, it dose-dependently inhibited the engulfment (Fig. 3B) . On the other hand, MFG-E8 Ϫ/Ϫ thioglycollate-elicited peritoneal macrophages responded to hMFG-E8 like NIH3T3 expressing ␣ v ␤ 3 . We interpret these results as shown in Figure 3C , in which below the optimal concentration, a single molecule of MFG-E8 binds to phosphatidylserine and ␣ v ␤ 3 integrin and functions as a bridging molecule. At higher concentrations, however, different MFG-E8 molecules bind to the phosphatidylserine on the apoptotic cells and ␣ v ␤ 3 integrin on the phagocytes, blocking its bridging function. The inhibitory effect of hMFG-E8 on the wild-type macrophages suggested that these macrophages were saturated with the endogenous MFG-E8, and an additional MFG-E8 inhibited the process.
MFG-E8 in the serum of hSLE patients
We previously showed that the lack of MFG-E8 causes a defect in the engulfment of apoptotic cells in the germinal centers of the spleen, which leads to the development of a SLE-type autoimmune disease [18] . The above results, showing that excess MFG-E8 caused inefficient engulfment of apoptotic cells, suggested that SLE-type autoimmune diseases might be caused by an excess of MFG-E8, as well as by its complete absence. To examine the possible involvement of MFG-E8 in human autoimmune diseases, two mAb against hMFG-E8 were raised in mice and Armenian hamsters, and they were used to develop an ELISA. The standard curve, generated with purified rhMFG-E8, showed the assay was sensitive to hMFG-E8 at the 100-pg level.
We then quantified the MFG-E8 levels in the serum or plasma samples from healthy volunteers (19 adults, 24 -45 years old, average age of 35; 30 children, 7-14 years old, average age of 11.6), adult SLE patients (172 patients, 18 -80 years old, average age of 43.2), and childhood-onset SLE patients (72 patients, 9 -37 years old, average age of 18.2) using the ELISA system. The samples from the healthy volunteers did not contain detectable levels of hMFG-E8 (i.e., their levels were lower than 3 ng/ml). On the other hand, MFG-E8 was detected at various levels in the samples from SLE patients. As shown in Figure 4 , 17 of the 172 adult SLE patients and 16 of the 72 childhood-onset SLE patients had 3-40 ng/ml MFG-E8 in their blood. After this measurement, the eight children with SLE whose serum had a high level of MFG-E8 received medical treatment for 7 months-3 years with improvement in all of the patients' symptoms. The serum MFG-E8 level was significantly lower in seven of the patients after treatment. In contrast, in the one patient who had the highest serum level MFG-E8 (25 ng/ml) at diagnosis, the serum level did not change after treatment, suggesting that this patient might constitutively express high levels of MFG-E8.
DISCUSSION
As the FACS analysis did not show the specific binding of mMFG-E8 to cells expressing ␣ v ␤ 3 , we previously concluded that MFG-E8 might not bind to the ␣ v ␤ 3 integrin on cells directly [17] . However, we showed here that hMFG-E8 binds the purified recombinant ␣ v ␤ 3 integrin with high affinity. This apparent discrepancy may be explained by the different affinity states of integrins used in the experiments. In resting cells, integrin ␣ v ␤ 3 assumes a bent conformation with low-ligand affinity [33, 34] , which must be "activated" to adopt extended conformation through an intracellular process termed "insideout signaling" to show appreciable affinity toward soluble ligands. This activation is mimicked by the addition of Mn 2ϩ in the experiment described in this paper. Extracellular signals, like chemokines and cell adhesion molecules, also trigger the activated configuration of the integrins [33] . When dying, apoptotic cells apparently produce a chemotactic signal(s) that works as a "find me" signal for macrophages [35] and may also function as an extracellular stimulus to activate integrins on macrophages.
Here, we found that hMFG-E8 supported the engulfment of apoptotic cells. hMFG-E8 carries two domains for binding phosphatidylserine: the C1 and C2 homologous domains and an RGD-containing EGF domain for binding integrins. Our results suggest that through these two domains, MFG-E8 works as a bridging molecule between apoptotic cells and integrinexpressing phagocytes. Interestingly, we also found that the effect of MFG-E8 on engulfment was dose-dependent but bellshaped: At low concentration, MFG-E8 stimulated engulfment, and this enhancing activity was lost at high concentrations. Our model for this binding behavior is as follows. At low concentrations, the open binding sites on apoptotic cells and phagocytes result in MFG-E8 molecules binding both cells to act as a bridge. At high concentrations, however, there are sufficient MFG-E8 molecules to saturate the binding sites presented on apoptotic cells (phosphatidylserine) and phagocytes (activated integrin), which prevent MFG-E8 molecules from binding both cell types and therefore, block their association (Fig. 3C) . A similar observation is reported for growth hormone and its receptor system [36] . That is, at low concentrations, a single growth hormone molecule binds to two receptors through two different binding sites and induces dimerization of the receptor, initiating signal transduction. In contrast, when the concentration of growth hormone is high, each receptor molecule is occupied by a different growth hormone and cannot be dimerized. When phagocytes were first preincubated with MFG-E8 and the unbound MFG-E8 then removed, no inhibitory effect of excess of MFG-E8 was observed (unpublished observation), supporting our model that phosphatidylserine and integrin are occupied by different MFG-E8 molecules at high MFG-E8 concentrations.
SLE is a multi-organ, autoimmune disease characterized by a wide array of clinical manifestations, from skin and mucosal Fig. 4 . MFG-E8 in blood of hSLE patients. (A) Standard curve for hMFG-E8 in the ELISA. Various amounts of rhMFG-E8 were diluted with TBS containing 0.1% Triton X-100 and 10% human serum or plasma from healthy donors. The solution was analyzed with an ELISA that uses two mAb against hMFG-E8, as described in Materials and Methods. (B) Serum or plasma levels of hMFG-E8 in patients determined by the ELISA. Sera or plasma from SLE patients and healthy volunteers were assayed by the ELISA for hMFG-E8.
lesions to severe injuries of the CNS, kidney, and other organs [11, 37] . We previously reported that the administration of MFG-E8 to mice causes SLE-type autoimmune disease [38] . Here, we found that some hSLE patients carry a high level of MFG-E8 in their serum. MFG-E8 is expressed in inflamed macrophages (thioglycollate-elicited macrophages) and immature dendritic cells [17, 19] . The MFG-E8 gene expression in macrophages is induced by proinflammatory cytokines such as GM-CSF and IL-18 (K. Miyasaka, and S. Nagata, unpublished results). It is possible that the high serum level of MFG-E8 is the secondary effect of SLE, or it is a result of the activation of the immune system in the patients. In any case, masking phosphatidylserine by an excess of MFG-E8 may inhibit not only the MFG-E8-dependent engulfment but also the engulfment with the phosphatidylserine receptor systems that were identified recently [32, 39, 40] and will worsen the SLE. In one patient, the serum MFG-E8 level did not change significantly after medical treatment, suggesting that this patient intrinsically expressed MFG-E8 at a high level. A nucleotide sequence analysis of the MFG-E8 gene of the patients who had high serum levels of MFG-E8 did not reveal any abnormalities (data not shown). A more detailed analysis of MFG-E8 gene expression at the transcriptional or translational level will be necessary to understand what causes its overexpression in these SLE patients. Finally, MFG-E8 is highly expressed in human breast tumors, probably through aberrant p63, a p53 gene family member [41, 42] . The ELISA system for hMFG-E8, established in this report, may be useful in the diagnosis of breast cancer.
